ImmunityBio (IBRX) Operating Income (2014 - 2026)
ImmunityBio (IBRX) reported Operating Income of -$69.8 million for Q1 2026, down 8.32% year-over-year from -$76.1 million in Q1 2025, and down 7.9% quarter-over-quarter from -$64.7 million in Q4 2025.
ImmunityBio (IBRX) Operating Income (2014 - 2026) Analysis & Trends
ImmunityBio (IBRX) has 13 years of Operating Income data on file, last reported at -$69.8 million in Q1 2026.
- Operating Income for Q1 2026 came in at -$69.8 million, down 8.32% year-over-year; the trailing twelve-month figure through Mar 2026 was -$261.4 million (up 16.6% YoY), and the FY2025 annual result was -$256.0 million, up 25.61% from the prior year.
- Operating Income slipped to -$69.8 million in Q1 2026 per IBRX's latest filing, from -$64.7 million in the prior quarter.
- Over five years, Operating Income peaked at -$55.6 million in Q3 2025 and troughed at -$111.6 million in Q1 2023.
- A 5-year average of -$81.4 million and a median of -$80.3 million in 2024 frame the typical range for Operating Income.
- The sharpest annual moves came in 2024 and 2025: Operating Income fell 16.66% in 2024, then soared 32.32% in 2025.
- A 5-year view of Operating Income shows it stood at -$84.9 million in 2022, then decreased by 0.58% to -$85.4 million in 2023, then climbed by 18.72% to -$69.4 million in 2024, then grew by 6.8% to -$64.7 million in 2025, then slipped by 7.9% to -$69.8 million in 2026.
- Business Quant data shows IBRX's Operating Income at -$69.8 million in Q1 2026, -$64.7 million in Q4 2025, and -$55.6 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Op. Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | -32.68 Mn |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -2.97 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | -19.70 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | -3.82 Mn |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -15.76 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 1.14 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -65.83 Mn |
| 10 | ImmunityBio | 7.55 Bn | 7.17 Bn | 43.97 Mn | -69.79 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -69.79 Mn |
| Dec 31, 2025 | -64.68 Mn |
| Sep 30, 2025 | -55.63 Mn |
| Jun 30, 2025 | -71.29 Mn |
| Mar 31, 2025 | -64.43 Mn |
| Dec 31, 2024 | -69.40 Mn |
| Sep 30, 2024 | -80.25 Mn |
| Jun 30, 2024 | -99.33 Mn |
| Mar 31, 2024 | -95.20 Mn |
| Dec 31, 2023 | -85.39 Mn |
| Sep 30, 2023 | -80.14 Mn |
| Jun 30, 2023 | -85.15 Mn |
| Mar 31, 2023 | -111.58 Mn |
| Dec 31, 2022 | -84.90 Mn |
| Sep 30, 2022 | -90.80 Mn |
| Jun 30, 2022 | -79.62 Mn |
| Mar 31, 2022 | -95.97 Mn |
| Dec 31, 2021 | -79.27 Mn |
| Sep 30, 2021 | -78.84 Mn |
| Jun 30, 2021 | -85.91 Mn |